Novo Nordisk A/S
🇩🇰Denmark
- Country
- 🇩🇰Denmark
- Ownership
- Public
- Established
- 1923-01-01
- Employees
- 63.3K
- Market Cap
- $602.2B
- Website
- http://www.novonordisk.com
Efficacy and Safety of Growth Hormone Treatment in Children Small for Gestational Age
Phase 3
Completed
- Conditions
- First Posted Date
- 2007-11-14
- Last Posted Date
- 2017-02-28
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 160
- Registration Number
- NCT00557336
- Locations
- 🇪🇸
Novo Nordisk Investigational Site, Zaragoza, Spain
Comparison of Insulin Detemir and Insulin Aspart in 2 Separate Injections Twice Daily to Extemporaneous Mixing Injection Regimen Twice Daily - The Paediatric Mixing Trial
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2007-10-11
- Last Posted Date
- 2014-11-02
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 25
- Registration Number
- NCT00542620
Comparison of the Blood Sugar Lowering Effect and Safety of Two Insulin Treatments in Type 2 Diabetes
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2007-10-01
- Last Posted Date
- 2017-03-10
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 296
- Registration Number
- NCT00537303
- Locations
- 🇬🇧
Novo Nordisk Investigational Site, Rugby, United Kingdom
Efficacy and Safety of Biphasic Insulin Aspart 30 in Type 2 Diabetes Mellitus When Failing on OADs
Phase 4
Completed
- Conditions
- Interventions
- First Posted Date
- 2007-10-01
- Last Posted Date
- 2014-12-08
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 161
- Registration Number
- NCT00537277
Efficacy Study of Recombinant Interleukin-21 in the Treatment of Ovarian Cancer
Phase 2
Completed
- Conditions
- Interventions
- First Posted Date
- 2007-08-31
- Last Posted Date
- 2017-03-01
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 10
- Registration Number
- NCT00523380
- Locations
- 🇩🇪
Novo Nordisk Investigational Site, Wiesbaden, Germany
Safety of Inhaled Preprandial Human Insulin in Subjects With Diabetes and Asthma
Phase 3
Terminated
- Conditions
- Interventions
- First Posted Date
- 2007-08-30
- Last Posted Date
- 2018-09-05
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 10
- Registration Number
- NCT00523042
- Locations
- 🇸🇰
Novo Nordisk Investigational Site, Zilina, Slovakia
The Effect of Insulin Detemir on Blood Glucose Control in Taiwanese Patients With Type 2 Diabetes Failing on OAD
Phase 4
Completed
- Conditions
- First Posted Date
- 2007-08-28
- Last Posted Date
- 2023-11-02
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 25
- Registration Number
- NCT00521690
Growth Hormone Treatment in Children Born Small for Gestational Age: Assessment of Satisfaction
Phase 4
Completed
- Conditions
- First Posted Date
- 2007-08-23
- Last Posted Date
- 2015-11-13
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 5
- Registration Number
- NCT00519844
Growth Hormone Deficiency in Adults (GHDA)
Phase 3
Completed
- Conditions
- First Posted Date
- 2007-08-22
- Last Posted Date
- 2017-02-28
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 121
- Registration Number
- NCT00519558
- Locations
- 🇯🇵
Novo Nordisk Investigational Site, Tokyo, Japan
Effect of Liraglutide or Exenatide Added to an Ongoing Treatment on Blood Glucose Control in Subjects With Type 2 Diabetes
Phase 3
Completed
- Conditions
- Interventions
- First Posted Date
- 2007-08-21
- Last Posted Date
- 2017-03-08
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 467
- Registration Number
- NCT00518882
- Locations
- 🇨🇭
Novo Nordisk Investigational Site, Lugano, Switzerland
© Copyright 2024. All Rights Reserved by MedPath